The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-02-01

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The macula has a very high concentration of photoreceptor cells - the cells that detect light. They send signals to the brain, which interprets them as images. The rest of the retina processes our peripheral, or side vision To explore whether cataract surgery evokes development or relapse of choroidal neovascularization (CNV) in wet age-related macular degeneration (AMD) patients followed for a 1-year postoperative period

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation

NCT00808197

Regional Blood Flow

COMPLETED NA

Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)

NCT00417846

Maculopathy, Age-Related Choroidal Neovascularization

COMPLETED

Macular Function During Anti-VEGF Treatment

NCT01023971

Age Related Macular Degeneration

UNKNOWN

OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT.

NCT05055973

Choroidal Neovascularization

UNKNOWN

Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion

NCT06757595

Retinal Vein Occlusion

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Age-related macular degeneration (AMD) is a leading cause of vision loss in adults over the age of 50. AMD causes damage to a small part of the retina responsible for central vision called the macula. When damage to the macula occurs, it typically causes loss of central, detailed vision which results in difficulty with tasks such as reading, driving, threading a needle, or recognizing faces.

Phacoemulsification is a modern-day cataract surgery that employs ultrasound energy to emulsify the nucleus, vacuum to catch the nuclear material, and irrigation and aspiration for cortex and viscoelastic removal.

It is currently impossible to draw definitive conclusions whether phacoemulsification (PhE) is safe for people with age-related macular degeneration (ARMD). It is not clear if PhE causes the progression of ARMD and affects visual acuity (VA). The purpose was to analyze the possible association of PhE with ARMD progression in the early and late (up to 18 months after surgery) period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular (wet) Age-Related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Above 50 years old

* not diabetic individuals
* wet ARMD

Exclusion Criteria

* intraoperative complications

* Eyes with diseases predisposing them for postoperative macular edema, preexisting macular edema, and eyes that developed cystoid macular edema
* active ocular inflammation or infection \_glaucoma
* A preoperatively worsened VA regardless phE
* ocular trauma
* patients with central retinal ischemia
* previous vitrectomy
* dry amd

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No